Justin Arnall, PharmD, FCCP, BCOP / Anthony J. Perissinotti, PharmD, BCOP - Dispensing High-Quality Care for Myelofibrosis: Pharmacist Leadership in Delivering Effective JAKi Therapy

About this episode

The episode discusses the role of pharmacists in delivering effective JAKi therapy for myelofibrosis.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KCA865. CME/CPE/IPCE credit will be available until April 30, 2027. Dispensing High-Quality Care for Myelofibrosis: Pharmacist Leadership in Delivering Effective JAKi Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This educational activity is supported by an independent medical education grant from GSK. Disclosure information is available at the beginning of the video presentation.

People in this episode

Guests: Justin Arnall, PharmD, FCCP, BCOP, Anthony J. Perissinotti, PharmD, BCOP

Topics covered

• myelofibrosis
• pharmacist leadership
• JAKi therapy
• patient care
• continuing education

Keywords

• myelofibrosis
• JAK inhibitors
• pharmacist leadership
• patient care
• continuing education

Sponsors

GSK

Mentioned in this episode

Organizations: PVI, PeerView Institute for Medical Education, Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), American Nurses Credentialing Center (ANCC)

More episodes of PeerView Clinical Pharmacology CME/CNE/CPE Video

• Andrew Kuykendall, MD - Ironing Out the Challenges of PV: Spotlight on Targeting the Hepcidin Pathway for Addressing Unmet Needs and Enhancing Patient Outcomes · June 5, 2026 · 32 min
• Brendon M. Stiles, MD - The Immunotherapy Playbook for Resectable NSCLC: Real-World Challenges and Practical Strategies · June 4, 2026 · 1h 6m
• Charise Gleason, MSN, NP-C, AOCNP / Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - “Off-the-Shelf” Choices in RRMM: Oncology Nurse Guidance on Delivering Quality Care With BCMA and Non-BCMA Immunotherapy · May 29, 2026 · 60 min
• Anna Chodos, MD, MPH - Getting Ahead of Cognitive Decline—Applying Patient-Centered Strategies to Assess and Reduce Dementia Risk in Primary Care: An AI-Guided Case Simulation Activity · May 29, 2026 · 46 min
• Adam Friedman, MD, FAAD - Wheals of Fortune: Chronic Spontaneous Urticaria Challenges and the Road to Resolution · May 29, 2026 · 55 min
• Anita Afzali, MD, MPH, MHCM, FACG, AGAF / Jessica R. Allegretti, MD, MPH, FACG, AGAF / Millie D. Long, MD, MPH - At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition · May 29, 2026 · 1h 11m